India Spares Merck Sec 3(d) Sword, Blocks Glenmark’s Sitagliptin
This article was originally published in PharmAsia News
Executive Summary
In a keenly watched decision, an Indian court has granted an interim injunction to Merck over its anti-diabetes drugs Januvia and Janumet, effectively blocking generic copies launched by Glenmark in 2013.